State regulations associated with late-stage cancer diagnoses
the ONA take:
According to a new study conducted by researchers at Georgia State University's School of Public Health in Atlanta and the University of North Carolina at Chapel Hill, state regulations of health insurance and practitioners are significantly associated with time receive breast or colorectal cancer diagnoses.
For the study, researchers evaluated states' regulatory policies and cancer cases reported between 2004 and 2009 in 40 states using the United States Cancer Statistics (USCS) database.
Results showed that 54% to 60% of newly diagnoses cases of colorectal cancer are diagnosed as late-stage cancer, and 24% to 36% of newly diagnosed breast cancers are diagnosed as late-stage.
Of note, the study was conducted between 2010 when the Affordable Care Act was enacted, making cancer screenings more widely available to Americans.
The study was published in the journal Health Economics Review.
State regulations of health insurance and practitioners are significantly associated with time receive breast or colorectal cancer diagnoses.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|